ALNYLAM PHARMACEUTICALS INC's ticker is ALNY and the CUSIP is 02043Q107. A total of 471 filers reported holding ALNYLAM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About ALNYLAM PHARMACEUTICALS INC
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company that specializes in RNA interference (RNAi) therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam's mission is to develop innovative RNAi-based therapies that can improve the lives of patients with genetic and other diseases.
Alnylam has a robust pipeline of RNAi therapeutics in various stages of development. The company's lead product, Onpattro, was approved by the FDA in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). Onpattro is the first RNAi therapeutic to receive FDA approval and represents a significant milestone for Alnylam.
In addition to Onpattro, Alnylam has several other RNAi therapeutics in development for the treatment of various diseases, including acute hepatic porphyrias, primary hyperoxaluria type 1, and ATTR amyloidosis with cardiomyopathy. The company is also exploring the potential of RNAi therapeutics in oncology and has several preclinical programs in this area.
Alnylam has a strong management team led by CEO John Maraganore, who has been with the company since its inception. The company has also formed strategic partnerships with other biopharmaceutical companies, including Sanofi and Regeneron, to advance its RNAi therapeutics.
Overall, Alnylam Pharmaceuticals Inc. is a promising biopharmaceutical company with a focus on developing innovative RNAi therapeutics for the treatment of genetic and other diseases. With a strong pipeline and strategic partnerships, Alnylam is well-positioned to continue making significant contributions to the field of RNAi therapeutics.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $356,481 | +62.6% | 1,467 | 0.0% | 0.03% | +64.7% |
| Q1 2024 | $219,243 | -24.2% | 1,467 | -3.0% | 0.02% | -29.2% |
| Q4 2023 | $289,412 | +72.7% | 1,512 | +59.8% | 0.02% | +84.6% |
| Q3 2023 | $167,537 | -6.8% | 946 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $179,683 | -92.0% | 946 | -91.6% | 0.01% | -56.7% |
| Q1 2023 | $2,256,004 | -15.7% | 11,262 | 0.0% | 0.03% | -25.0% |
| Q4 2022 | $2,676,414 | -99.9% | 11,262 | +8.3% | 0.04% | +25.0% |
| Q3 2022 | $2,081,865,000 | +67.5% | 10,401 | +22.0% | 0.03% | +100.0% |
| Q2 2022 | $1,243,225,000 | -10.7% | 8,524 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $1,391,884,000 | -3.7% | 8,524 | 0.0% | 0.02% | +6.7% |
| Q4 2021 | $1,445,500,000 | -30.2% | 8,524 | -22.3% | 0.02% | -31.8% |
| Q3 2021 | $2,071,057,000 | +11.4% | 10,969 | 0.0% | 0.02% | +15.8% |
| Q2 2021 | $1,859,465,000 | +20.1% | 10,969 | 0.0% | 0.02% | +11.8% |
| Q1 2021 | $1,548,713,000 | +8.6% | 10,969 | 0.0% | 0.02% | +6.2% |
| Q4 2020 | $1,425,641,000 | -10.7% | 10,969 | 0.0% | 0.02% | -27.3% |
| Q3 2020 | $1,597,086,000 | -1.7% | 10,969 | 0.0% | 0.02% | -8.3% |
| Q2 2020 | $1,624,619,000 | +36.1% | 10,969 | 0.0% | 0.02% | +14.3% |
| Q1 2020 | $1,193,976,000 | -5.5% | 10,969 | 0.0% | 0.02% | +31.2% |
| Q4 2019 | $1,263,300,000 | +176.1% | 10,969 | +92.8% | 0.02% | +166.7% |
| Q3 2019 | $457,509,000 | +10.8% | 5,689 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $412,794,000 | -22.4% | 5,689 | 0.0% | 0.01% | -33.3% |
| Q1 2019 | $531,637,000 | +28.2% | 5,689 | 0.0% | 0.01% | +28.6% |
| Q4 2018 | $414,785,000 | -16.7% | 5,689 | 0.0% | 0.01% | -22.2% |
| Q3 2018 | $497,901,000 | -11.1% | 5,689 | 0.0% | 0.01% | -18.2% |
| Q2 2018 | $560,310,000 | -17.3% | 5,689 | 0.0% | 0.01% | -21.4% |
| Q1 2018 | $677,560,000 | -6.3% | 5,689 | 0.0% | 0.01% | -12.5% |
| Q4 2017 | $722,788,000 | +149.5% | 5,689 | +33.1% | 0.02% | +433.3% |
| Q3 2016 | $289,692,000 | +22.1% | 4,274 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $237,165,000 | +17.4% | 4,274 | +32.9% | 0.00% | +50.0% |
| Q1 2016 | $201,931,000 | -33.3% | 3,217 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $302,848,000 | -75.5% | 3,217 | -79.1% | 0.00% | -78.6% |
| Q3 2015 | $1,236,018,000 | +1966.4% | 15,381 | +2982.4% | 0.01% | +1300.0% |
| Q2 2015 | $59,815,000 | – | 499 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RTW INVESTMENTS, LP | 1,683,362 | $319,737,778 | 6.09% |
| Eagle Health Investments LP | 136,756 | $25,975,435 | 4.86% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 81,600 | $15,499,104 | 4.72% |
| Casdin Capital, LLC | 280,000 | $53,183,200 | 4.65% |
| Parametrica Management Ltd | 10,246 | $1,946,125 | 3.75% |
| Karani Asset Management LLC | 15,245 | $2,895,635 | 2.92% |
| Avoro Capital Advisors LLC | 1,105,000 | $209,883,700 | 2.85% |
| Bellevue Group AG | 899,650 | $170,879,521 | 2.44% |
| ROSENBLUM SILVERMAN SUTTON S F INC /CA | 37,153 | $7,056,841 | 2.33% |
| Tri Locum Partners LP | 29,506 | $5,604,370 | 2.08% |